Participating Companies

BerGenBio
[BGBIO:OS]
NKr2,735 MM MCap
Developing first-in-class selective Axl kinase inhibitors for liquid and solid cancers, lead candidate is bemcentinib (BGB324) in four company-sponsored trials. [more information]

Exicure
[XCUR]
$167 MM MCap
Cavrotolimod (AST-008) in Ph2 trials for patients with Merkel Cell Carcinoma and Cutaneous Squamous Cell Carcinoma, with Ph1b data presented at AACR 2020. XCUR-FXN in preclinical development for patients with Friedreich's Ataxia, using genetically targeted SNA therapies to remove FXN transcription blockage. [more information]

Lineage Cell Therapeutics Inc.
[LCTX]
$369 MM MCap
Cell therapy company with 3 clnical programs 1) OpRegen, an RPE transplant therapy in Ph1/2a development for the treatment of dry-AMD. 2) OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries with Orphan and RMAT designations. 3) VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells currently in a Ph 1 for NSCLC conducted by CRUK. [more information]

Sol-Gel Technologies Ltd.
[SLGL]
$308 MM MCap
Commercializing branded generic topical drug products (skin diseases). Two positive Phase 3 programs, both with PDUFA dates in 2021: Epsolay has potential to be first FDA-approved single-agent benzoyl peroxide prescription drug product for rosacea (PDUFA date on April 26th). Twyneo has potential to be the first acne treatment that contains fixed dose combination of BPO and tretinoin (PDUFA date on August 1st). [more information]

Zentalis
[ZNTL]
$1,929 MM MCap
Discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. Broad pipeline of potentially best-in-class oncology candidates, including ZN-c5, an oral selective estrogen receptor degrader for ER+/HER2- breast cancer, ZN-c3, a WEE1 inhibitor, ZN-d5, a BCL-2 inhibitor and ZN-e4, an EGFR inhibitor. [more information]